T-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for T-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Newly-diagnosed Pediatric T-cell ALL Protocol [Phase 2, Phase 3]
This clinical trial update describes a pediatric protocol for newly diagnosed T-cell acute lymphoblastic leukemia entering Phase 2/3 and cur…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating OBI-3424 in patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, …
-
FDA approval · 2025-07-25FDA Approved: NELARABINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Nelarabine by Zydus Lifesciences Limited under ANDA 215037. This action updates the regulatory s…
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" [Phase 2]
An ongoing Phase 2 trial is evaluating Daratumumab (Darzalex) for residual disease in T-cell acute lymphoblastic leukemia, with recruiting s…
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations [Phase 2]
Phase 2 trial evaluating the combination of venetoclax and azacitidine for newly diagnosed early T-cell precursor acute lymphoblastic leukem…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD7 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell malignancies has completed, assessing safet…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia [EARLY_Phase 1]
This clinical trial update reports on an early-phase (Phase 1) study evaluating the safety and efficacy of the investigational therapy VGO-C…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: Venetoclax Based Regimen for R/R T-ALL [Phase 2]
Phase 2 trial evaluating a venetoclax-based regimen for relapsed/refractory T-cell acute lymphoblastic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia [Phase 1]
Phase 1 trial of XmAb18968 (CD3-CD38) in relapsed or refractory acute myeloid leukemia and T-cell lymphoblastic leukemia/lymphoma has been t…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention [Phase 2]
A Phase 2 clinical trial is evaluating a combination of demethylating agents with venetoclax to prevent relapse in patients with high-risk T…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) [Phase 1]
Phase 1 clinical trial assessing a preventive therapy to reduce graft-versus-host disease in participants with hematologic malignancies unde…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trials are evaluating CAR-T cell therapy for relapsed or refractory malignant hematologic tumors, including aggressi…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial evaluating a CD5-targeted CAR-NK cell therapy for relapsed/refractory T-cell hematologic malignancies (T-ALL and T-ce…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a nanobody-based anti-CD5 CAR-T cell therapy for relapsed/refractory precursor T-cell lymphoblastic leukemia/ly…
-
FDA approval · 2025-03-11FDA Approved: ARRANON — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Arranon (nelarabine) filed by Sandoz Inc., resulting in changes to the product's labeling.
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) [Phase 1, Phase 2]
This update describes BEAM-201, a study in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, in Pha…
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: VHAG in Treating R/R T-ALL/LBL [Phase 2]
Phase 2 clinical trial evaluating VHAG for relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, curren…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL [EARLY_Phase 1]
A Phase 1 trial evaluating CD7-directed CAR-T therapy for relapsed/refractory CD7-positive T-cell acute lymphoblastic leukemia and T-lymphob…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) [EARLY_Phase 1]
This early-phase (Phase 1) clinical trial update reports completion of a study evaluating CD7-targeted CAR-T cell therapy in patients with r…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL [EARLY_Phase 1]
A Phase 1 trial evaluating RD13-02 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell acute lymphoblastic leukemia and T-lymphob…
-
CLINICAL_TRIALS other · 2024-11-20Clinical Trial Update: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
Clinical trial update on the long-term safety follow-up of WU-CART-007 showing the study is currently enrolling by invitation for patients w…
-
CLINICAL_TRIALS trial_result · 2024-11-14Clinical Trial Update: Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma [Phase 1]
Phase I trial update for autologous CD7-CAR T cell therapy in high-risk acute T-cell leukemia/lymphoma; the study has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-14Clinical Trial Update: Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia [Phase 1]
This document notes the termination of a Phase 1 clinical trial evaluating donor-derived CD5 CAR T cells for relapsed or refractory T-cell a…
-
CLINICAL_TRIALS withdrawal · 2024-11-14Clinical Trial Update: Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma [Phase 1]
A Phase 1 trial of donor-derived CD5 CAR T cells (CT125B) for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma has been w…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells [Phase 1, Phase 2]
An ongoing Phase 1/2 clinical trial evaluating sequential CD5/CD7-specific CAR-T cells for CD5/CD7-positive T-cell malignancies including T-…